Právní předpis byl sestaven k datu 25.07.2019.
Zobrazené znění právního předpisu je účinné od 04.01.2018 do 25.07.2019.
80
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. m. x. a č. 46/2008 Sb. x. x.
Xxxxxxxxxxxx zahraničních věcí xxxxxxx, že dne 28. xxxxxxxxx 2016 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X (Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xxx rok 2017 - Xxxxxxxxxxx xxxxxxxx) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx1).
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx I Českou xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx X vstoupilo x xxxxxxxx x souladu x článkem 34 odst. 3 Úmluvy xxx 1. xxxxx 2017 x pro Českou xxxxxxxxx xxxxxxxxx x xxxxxxxx dne 30. xxxxx 2017.
Xxxx vstupu xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx I xxxxxx xx 1. xxxxx 2016, vyhlášené xxx č. 26/2017 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X a xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
XXXXXXX XXXXXXXXXXXXX XXXXX
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2017
XXXXXXXXXXX XXXXXXXX
Xxxxxxxxx xxxx Seznamu xxxx xxxxxxxxx WADA a xxxx publikován x xxxxxxxxxx x francouzštině.
V xxxxxxx jakýchkoliv xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx bude xxxxxxxxxxx anglická verze.
Tento Xxxxxx xxxx xxxxxx xx 1. xxxxx 2017
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2017
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2017
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 a M3.
|
LÁTKY X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX) |
XXXXXXXX LÁTKY
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxxx xxxxxx látka, která xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Xxxxxxx x není aktuálně xxxxxxxxx pro humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu výzkumu xxxx xx ukončené xxxxxxxxxx, syntetické drogy, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx zakázána xxxxx.
X1. XXXXXXXXXX LÁTKY
Anabolické xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, zahrnující:
1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);
1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);
bolandiol (xxxx-4-xx-3ß, 17ß-xxxx);
xxxxxxxxxx;
xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);
dehydrochlormethyltestosteron (4-chloro-17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);
desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);
xxxxxxxxxxx;
xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);
xxxxxxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17ß-ol);
gestrinon;
4-hydroxytestosteron (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);
xxxxxxxxxx;
xxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);
metenolon;
methandriol;
metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);
xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);
xxxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);
methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);
xxxxxXxxxxxxxxxxx;
xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);
xxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxxxxx;
xxxxxxxxxxxx;
xxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxx (17ß-[(tetrahydropyran-2-yl)oxy]-1’H-pyrazolo[3,4:2,3]-5α-androstane);
quinbolon;
stanozolol;
stenbolon;
1-testosteron (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);
xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);
trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
x. Endogenní** XXX, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);
androstendion (androst-4-en-3,17-dion);
boldenon;
boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);
xxxxxxxxxxxxxxxxxx (17ß-hydroxy-5α-androstan-3on);
nandrolon (19-xxxxxxxxxxxxxx);
19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);
19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);
testosteron;
a jejich xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx;
5α-xxxxxxxxx-3α,17ß-xxxx;
5α-xxxxxxxxx-3ß,17α-xxxx;
5α-xxxxxxxxx-3ß,17ß-xxxx;
5ß-xxxxxxxxx-3α,17ß-xxxx;
5α-xxxxxxx-2-xx-17-xx;
xxxxxxx-4-xx-3α,17α-xxxx;
xxxxxxx-4-xx-3α,17ß-xxxx;
xxxxxxx-4-xx-3ß,17α-xxxx;
xxxxxxx-5-xx-3α,17α-xxxx;
xxxxxxx-5-xx-3α,17ß-xxxx;
xxxxxxx-5-xx-3ß,17α-xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);
xxxxxxxxxxx;
xxx-xxxxxxxxxxxxxxxxxx;
xxxxxxxxxxxxxx;
xxxxxxxxxxxxxx;
3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;
7α-xxxxxxx-XXXX;
7ß-xxxxxxx-XXXX;
7-xxxx-XXXX;
19-xxxxxxxxxxxxxx;
19-xxxxxxxxxxxxxxxxx.
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM, xxxx. xxxxxxx a xxxxxxx); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
|
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx přirozeně xxxxxxxxx. |
X2. XXXXXXXXX HORMONY, XXXXXXX FAKTORY, PŘÍBUZNÉ XXXXX X XXXXXXXX
Xxxxxxxxxxx xxxxx x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx xxxx xxxxxxxx:
1. Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx:
1.1 Látky xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx např.
darbepoetinu (dEPO);
erytropoetinů (XXX);
XXX-Xx;
XXX-xxxxxxxxxxx xxxxxxx (EMP), xxxx. CNTO 530 x peginesatid;
inhibitory GATA, xxxx. K-11706;
methoxypolyethylenglykol-epoetin xxxx (XXXX);
xxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx beta (XXX-xxxx), xxxx. xxxxxxxxxxx, luspatercept;
1.2 Xxxxxxxx xxxxxxxxxxxxxxxxxx EPO xxxxxxxxx, xxxx.
XXX-290;
xxxxxx XXX;
xxxxxxxxxxxxx XXX;
2. Xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx. xxxxxx, molidustat x xxxxxxxxxx (XX-4592); x aktivátory XXX, xxxx. argon a xxxxx.
3. Choriogonadotropin (XX) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxx, gonadorelin a xxxxxxxxxxx, x xxxx.
4. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx.
5. Xxxxxxx xxxxxx (XX) a jeho xxxxxxxxxx xxxxxxx xxxxxx: xxxxxxx xxxxxxxxxxxx růstový xxxxxx (XXXX) x xxxx xxxxxxx, např. XXX-1295, sermorelinu x xxxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxxx x mimetik xxxxxxxx, např. xxxxxxxxxxx x ipamorelinu; xxxxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxxx, XXXX-6, hexarelinu a xxxxxxxxxxxx (XXXX- 2).
Kromě xxxx xxxx zakázány xxxxxxxxxxx růstové xxxxxxx:
Xxxxxxxxxxxxx xxxxxxx faktory (XXXx); xxxxxxxxxxxx růstový faktor (XXX); insulinu xxxxxxx xxxxxxx faktor-1 (XXX-1) x jeho xxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxx (XXX); xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx růstové faktory xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx svalů, xxxxx x vaziva, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx selektivní x xxxxxxxxxxxx beta2- xxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.
Xxxxxxxx (xxx xx x xxxxxxxx xxxxx na xx):
Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salbutamol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.
Xxxxxxxx jsou:
- inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx, xxxxxxxxxxx 800 xxxxxxxxxx xx xxxxxxx 12 xxxxx;
- xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 mikrogramů xx 24 hodin;
- inhalační salmeterol: xxxxxxxxx 200 mikrogramů xx 24 hodin.
Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní nález, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx farmakokinetickou studií, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx (v xxxxxxxx) nižší, xxx xxxx xxxxxxx maximální xxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX MODULÁTORY
Zakázané xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:
1. Inhibitory xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);
androsta-3,5-dien-7-17-dion (xxxxxxxxx);
4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);
xxxxxxxxx;
xxxxxxxxx;
xxxxxxxx;
xxxxxxxxxxx,
xxx xx x xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), zahrnující:
Raloxifen;
xxxxxxxxx;
xxxxxxxxx, xxx ne x xxxxxxxx xxxxx na xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:
Cyklofenil; fulvestrant x xxxxxxxx, xxx xx s omezením xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx ne
s xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx modulátory:
5.1 Xxxxxxxxxx AMP-aktivované proteinkinázy (XXXX), xxxx. XXXXX; x Xxxxxxxx Receptoru xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. XX 1516;
5.2 Insuliny x xxxxxxxx insulinů;
5.3 Xxxxxxxxx;
5.4 Trimetazidin.
S5. XXXXXXXXX X XXXXXXXXX LÁTKY
Následující xxxxxxxxx x xxxxxxxxx xxxxx jsou xxxxxxxx, xxxxxx jako další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx a xxxxxxxxx xxxxxxxxxxxx účinky.
Zahrnují:
-
Desmopressin, xxxxxxxxxxxxxxx (např. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx, xxx xx x omezením xxxxx xx ně.
-
Acetazolamid, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x vaptany (xxxx. tolvaptan), ale xx x xxxxxxxx xxxxx na ně.
S xxxxxxxx:
-
xxxxxxxxxxxx, pamabromu x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)
-
Xxxxxxxxx xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxxx
Xxxxx jakéhokoliv xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxx
xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx maskovací xxxxxx, xxxx považováno xx Pozitivní xxxxxxxxxxx xxxxx, xxxxx Sportovec xxxx xxxxxxxxxx Terapeutickou xxxxxxx (XX) xx xxxx látku xxxxx x té, která xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
X1. MANIPULACE X XXXX X KREVNÍMI XXXXXXXXXXXX
Xxxxxxxx je následující:
1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx produktů xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx.
2. Umělé xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx:
xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např. xxxxxx xxxxxxxx založené xx xxxxxxxxxxx a xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx xxxxx xx xx. Xxxxxxxxx suplementace xxxxxxxx zakázána není.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Vzorků odebraných xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx úpravu (xxxx. xxxxxxxxxx) moči, xxx xx s xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx více xxx 50 ml xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. GENOVÝ XXXXXX
X xxxxxx potenciálu xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx polymerů xxxxxxxxxx xxxxxxx xxxx jejich xxxxxxx;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
|
XXXXX X XXXXXX XXXXXXXX PŘI XXXXXXX |
Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx
xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. STIMULANCIA
Všechna xxxxxxxxxxx xxxxxx všech xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. d- x I-, xxxx xxxxxxxx.
Xxxxxxxxxxx zahrnují:
(a) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxxx /4-fenylpiracetam (karfedon)/,
furfenorex,
klobenzorex,
kokain,
kropropamid,
krotetamid,
lisdexamfetamin,
mefenorex,
mefentermin,
metamfetamin (x-),
xxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxxxxx,
x-xxxxxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx.
Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx ně):
Adrenalin (epinefrin)****,
benzfetamin,
dimethylamfetamin,
efedrin***,
etamivan,
etylamfetamin,
etylefrin,
famprofazon,
fenbutrazát,
fenetylamin x jeho xxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),
xxxxxxxxxxxx,
xxxxx**,
xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx),
xxxxxxxxxxxxxxx,
xxxxxxxxxxxx,
xxxxxxxxxxxx***,
xxxxxxxxxxxxxxxxxxxxxxxx,
xxxxxxxxxxxx,
4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxx (metylsynefrin),
pemolin,
pentetrazol,
propylhexedrin,
pseudoefedrin*****,
selegilin,
sibutramin,
strychnin,
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx),
xxxxxxxxxxxxx
x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx.
X xxxxxxxx:
-
xxxxxxxxx
-
xxxxxxxx xxxxxxxxx x případě jejich xxxxxxxx/xxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2017*.
* Bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x xxxxxx považovány xx Zakázané xxxxx.
** Xxxxx: xx zakázaný xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
*** Efedrin x xxxxxxxxxxxxx: jsou xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.
**** Adrenalin (xxxxxxxxx): xxxx xxxxxxx xxx lokálním xxxxxx, xxxx. xxxxx, oční xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky.
***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx koncentrace x xxxx je xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.
X7. NARKOTIKA
Zakázané xx xxxxxxxxxxx:
Xxxxxxxxxxx,
xxxxxxxxxxxxx,
xxxxxxxxx(xxxxxx),
xxxxxxxx a xxxx deriváty,
hydromorfon,
metadon,
morfin,
nikomorfin,
oxykodon,
oxymorfon,
pentazocin,
petidin.
S8. XXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
-
Xxxxxxxx (xxxx. xxxxx, konopí a xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).
-
Xxxxxxxxxxxxxx, xxxx. "Xxxxx", XXX018, XXX073 x XX-210.
X9. XXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
|
XXXXX ZAKÁZANÉ X&xxxx;XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx krve. Xxxxxxx xxxxxxx xxx porušení xxxxxxxxxxx pravidla xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0,10 x/x.
-
Xxxxxxxxxxxx xxxxx (XXX)
-
Xxxxxxxxxxx (XX)
-
Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
-
Xxxxx motorismus (XXX)
X2. BETA-BLOKÁTORY
Beta-blokátory xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, x xxx xx to xxxxxxxx x Xxxx soutěž.
-
Automobilový xxxxx (FIA)
-
Billiard (xxxxxxx xxxxxxxxxx) (XXXX)
-
Xxxx (XXX)
-
Xxxxxxxxxxx (XX)*
-
Xxxxxxxx (XXX) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x U-rampa, x xxxxxxxxx U-rampa x "xxx xxx"
-
Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x xxxxxxxxxxxx xxxxxxxxxx xxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxxxxxxx xxxxx s xxxxxxxxx xxxx bez xxxxxxx, free xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x xxxxxxxxxx váha.
-
Střelba (XXXX, XXX)*
-
Xxxxx (XXX)
* Xxxxxxxx také Xxxx xxxxxx
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxx,
xxxxxxxxx,
xxxxxxxxxx,
xxxxxxx,
xxxxxxxxxx,
xxxxxxx,
xxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxx,
xxxxxxxxxx,
xxxxxxxx,
xxxxxxxxxxx,
xxxxxxx,
xxxxxxx,
xxx xx x xxxxxxxx pouze xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 80/2017 Sb. m. x. xxxxx xxxxxxxxx xxxx 4.1.2018.
Xxxxxx předpis x. 80/2017 Sb. x. x. xxx xxxxxx právním předpisem č. 36/2019 Sb. m. s. x účinností xx 26.7.2019.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného právního xxxxxxxx.
1) Mezinárodní úmluva xxxxx dopingu xx xxxxxx, přijatá xxx 19. října 2005 x Paříži, byla xxxxxxxxx v xxxxxxxxx xxxxx x s xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.
Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.